Deciphera Pharmaceuticals (DCPH) Shares Down 18.3%

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) shares fell 18.3% during mid-day trading on Friday . The company traded as low as $22.05 and last traded at $22.26. 1,036,294 shares traded hands during trading, an increase of 412% from the average session volume of 202,333 shares. The stock had previously closed at $27.23.

A number of brokerages have recently issued reports on DCPH. Canaccord Genuity began coverage on Deciphera Pharmaceuticals in a research note on Tuesday, August 7th. They set a “buy” rating and a $55.00 price objective on the stock. Zacks Investment Research cut Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 3rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a research note on Wednesday, October 3rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $47.55.

The company has a debt-to-equity ratio of 0.05, a current ratio of 18.44 and a quick ratio of 18.44. The company has a market capitalization of $1.08 billion and a PE ratio of -9.11.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. On average, equities analysts anticipate that Deciphera Pharmaceuticals Inc will post -2.61 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of DCPH. Bank of America Corp DE grew its stake in shares of Deciphera Pharmaceuticals by 316.1% in the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after purchasing an additional 1,982 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Deciphera Pharmaceuticals by 37.5% in the first quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after purchasing an additional 2,700 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Deciphera Pharmaceuticals in the second quarter worth about $203,000. Rhumbline Advisers bought a new stake in shares of Deciphera Pharmaceuticals in the second quarter worth about $301,000. Finally, Highland Capital Management LP bought a new stake in shares of Deciphera Pharmaceuticals in the second quarter worth about $394,000. 53.52% of the stock is currently owned by institutional investors.

About Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Further Reading: Call Option

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply